Real-life Effectiveness and Cost-effectiveness of Qvar Versus FP and BDP in the Management of COPD
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the effectiveness, cost-effectiveness and direct
healthcare costs of managing chronic obstructive pulmonary disease (COPD) in primary care
patients with evidence of COPD who either initiate inhaled corticosteroid (ICS) therapy, or
have an increase in their ICS dose, as hydrofluoroalkane (HFA) beclometasone dipropionate
(BDP) (hereafter Qvar®), CFC-BDP (hereafter BDP) and fluticasone propionate (FP) via
pressurised metered-dose inhalers.
Details
Lead Sponsor:
Research in Real-Life Ltd
Collaborators:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries